TG THERAPEUTICS, INC.;RHIZEN PHARMACEUTICALS SA;LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
发明人:
Michael S. Weiss,Hari P. Miskin,Peter Sportelli,Swaroop K.V.S. Vakkalanka
申请号：
US14440139
公开号：
US20150290317A1
申请日:
2013.11.01
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
